SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending as investors discuss its potential for a short squeeze and compare its valuation to competitors like Robinhood. Community members are highlighting strong revenue growth, increasing customer assets, and expansion into new markets as reasons for optimism. Concerns about the company's China connection are also being addressed by some investors, who emphasize its U.S. regulation and asset protection.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

SNDX is trending as traders actively discuss option activity and recent analyst ratings, including an upgrade from Barclays. Community members are weighing the potential impact of short positions and upcoming presentations at the ASH meeting. Some are also speculating about a possible acquisition by Incyte, highlighting the synergy between the companies and SNDX's undervalued status compared to its peers in the oncology space.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending due to concerns about its AI strategy, particularly its relationship with OpenAI and the debt undertaken to support related infrastructure; these concerns have led to significant price drops and increased short interest, sparking discussions about a potential short squeeze and the company's future prospects within the AI landscape. Community perspectives are divided, with some viewing the pullback as a buying opportunity and others expressing deep skepticism about the management's direction. The broader context includes comparisons to other tech giants and debates over the sustainability of Oracle's approach.

Nukkleus, Inc. is a financial technology company, which engages in the provision of blockchain-enabled technology solutions. It also offers software and technology solutions for worldwide crypto and foreign exchange transactions with a focus on the movement of funds via crypto rails and back-to-back access to fiat conversion in a compliant regulated fashion. It operates through the following geographical segments: United States, United Kingdom, and Malta. The company was founded on May 24, 2019 and is headquartered in New York, NY.

Nukkleus Inc - Ordinary Shares - New

Nukkleus Inc

Nukkleus Inc. is trending as discussions revolve around its pending acquisition of Star 26 Capital and potential benefits from increased defense spending, particularly related to Iron Dome technologies. The community is analyzing the implications of the acquisition, potential synergies, and upcoming milestones, while some express concerns about dilution and financial health. Bullish sentiment is fueled by expectations of a short squeeze and the company's pivot to the aerospace and defense sectors.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell is trending as investors digest its AI server shipment forecast and backlog, with some analysts highlighting the company's potential to benefit from increased AI infrastructure spending. Community discussions revolve around Dell's valuation, growth prospects, and competitive positioning against rivals like SMCI. The stock's movements are also influenced by broader market trends and analyst ratings, creating a mix of bullish and bearish sentiment.

Avici

Avici ($AVICI) is trending as a novel crypto-banking project on Solana gaining attention for its Visa-compatible credit cards and potential to disrupt traditional finance. The community is focused on its real-world applications, self-custodial features, and significant recent price appreciation, while also speculating about future CEX listings.

Kohl's Corp. engages in the operation of family-oriented department stores. Its business line includes apparel, footwear, and accessories for women, men, and children, home products, beauty products, and accessories. The stores generally carry a consistent merchandise assortment with some differences attributable to regional preferences. The company was founded in 1962 and is headquartered in Menomonee Falls, WI.

Kohl`s Corp.

Kohl's Corp

Kohl's ($KSS) is trending as traders discuss a potential short squeeze, fueled by high short interest and a recent positive shift in sentiment. Community members are weighing the retailer's long-term value against short-term trading opportunities, with some eyeing a continued climb and others anticipating a pullback. The stock's performance is being closely watched within the context of the broader retail sector and upcoming earnings.

Autodesk, Inc. engages in the design of software and services. Its products include AutoCAD, BIM Collaborate Pro, Revit, Civil 3D, Fusion 360, InfraWorks, Inventor, Maya, PlanGrid, Revit, Shotgun, and 3ds Max. The firm also offers product development and manufacturing software, which provides manufacturers in the automotive, transportation, industrial machinery, consumer products, and building product industries with digital design, engineering, and production solutions. The firm is also involved in digital media and entertainment, which consists of tools for digital sculpting, modeling, animation, effects, rendering, and compositing for design visualization, visual effects, and games production. The company was founded by John Walker in April 1982 and is headquartered in San Francisco, CA.

Autodesk Inc.

Autodesk is trending amid discussions of strong Q3 results, driven by cloud subscriptions and AI integration, despite some short-selling activity. Upgrades from DB and Rosenblatt are contributing to positive sentiment, while the community also discusses options activity and potential upside. Investors are closely watching the design software maker's performance within the broader software sector.

Workday, Inc. engages in the provision of development of enterprise cloud applications for finance and human resources. It delivers financial management, human capital management and analytics applications designed for companies, educational institutions, and government agencies. The company was founded by David A. Duffield and Aneel Bhusri in 2005 and is headquartered in Pleasanton, CA.

Workday Inc - Ordinary Shares - Class A

Workday Inc

Workday is trending following its latest earnings report and forward guidance, with community discussion focused on subscription revenue and the impact of AI. While some analysts are reducing price targets, others remain optimistic about Workday's long-term growth potential and recent acquisitions. Technical analysis and options flow are also being heavily scrutinized to gauge potential future price movement.

Amentum Holdings, Inc. provides mission-critical, technology-driven services in government and commercial markets. It operates through two operating segments: Critical Mission Solutions and Cyber & Intelligence. The Critical Mission Solutions segment provides test, training, and operations services for missile defense systems, IT and engineering services to defense clients and the space sector, technological solutions, including installations, decommissioning, and environmental remediation to energy clients, and other highly technical consulting solutions. The Cyber & Intelligence segment provides advanced cyber training and data analytics for government professionals, advanced communication systems and aerial mapping technologies to national security clients, and other technical services for United States defense and intelligence clients. The company was founded on November 26, 2019 and is headquartered in Chantilly, VA.

Amentum Holdings Inc.

Amentum ($AMTM) is trending as investors discuss a recent Morgan Stanley upgrade and overall bullish market sentiment. The community highlights the company's potential for growth and significant contract wins, particularly in space, nuclear, and national security sectors. Bullish sentiment and upward price momentum have significantly driven up watchlists this week.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

In this photo illustration, the lCapricor Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

‘Pharma Bro’ Martin Shkreli Goes Short On Capricor Therapeutics – Stock Tumbles 17%

Shkreli said that the company’s only asset, Dermiocel, will not yield positive results in the HOPE-3 study.

Equity

Shkreli said that the company’s only asset, Dermiocel, will not yield positive results in the HOPE-3 study.


What is B. Riley's Forecast for CAPR FY2025 Earnings?

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) - Equities research analysts at B. Riley lowered their FY2025 earnings estimates for shares of Capricor Therapeutics in a research report...

What is Roth Capital's Estimate for CAPR FY2025 Earnings?

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) - Stock analysts at Roth Capital upped their FY2025 earnings per share estimates for shares of Capricor Therapeutics in a research note issued...

B. Riley Research Analysts Cut Earnings Estimates for CAPR

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) - Equities research analysts at B. Riley cut their FY2026 EPS estimates for shares of Capricor Therapeutics in a research note issued to...

CAPR FY2025 EPS Estimate Boosted by Cantor Fitzgerald

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) - Research analysts at Cantor Fitzgerald raised their FY2025 earnings per share estimates for Capricor Therapeutics in a research report issued...

HC Wainwright Has Positive Estimate for CAPR FY2025 Earnings

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) - Equities researchers at HC Wainwright lifted their FY2025 earnings per share estimates for shares of Capricor Therapeutics in a research...

Investors Purchase High Volume of Capricor Therapeutics Put Options (NASDAQ:CAPR)

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) was the target of unusually large options trading on Tuesday. Stock investors purchased 17,427 put options on the company. This is an...

Capricor Therapeutics (NASDAQ:CAPR) Issues Earnings Results

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) released its quarterly earnings results on Monday. The biotechnology company reported ($0.54) earnings per share for the quarter, meeting...

<ul class="summary-bullets"><li>Capricor plans to resubmit its Duchenne therapy application in 2026 with new cardiac efficacy data.</li><li>FDA signaled flexibility that could speed approval if results are strong.</li><li>Retail traders called the company’s RMAT status a potential “secret weapon.”</li></ul>Capricor Therapeutics shares rose over 3% in after-hours trading after the company said during its third-quarter conference call that it is rebuilding its approval bid for its Duchenne muscular dystrophy therapy, deramiocel, following an FDA rejection that requested additional safety, efficacy, and manufacturing data.The company said it plans to resubmit its Biologics License Application (BLA) in 2026, after the FDA indicated it would review the totality of data from its study rather than rely solely on skeletal muscle endpoints. The approach allows Capricor to highlight cardiac efficacy, a key determinant of disease progression in Duchenne-associated cardiomyopathy.<h2 class="st-heading-2">FDA Meeting Opens Door To Flexible Review</h2>While the Complete Response Letter (CRL) issued in July was unexpected, Capricor said on the call that Capricor was “well-positioned” to respond using data from its ongoing late-stage clinical trial, which is expected to report results within weeks.During an FDA Type A meeting in August, the agency said those trial results could be used to address the issues cited in the CRL. Capricor also asked the FDA to keep its current BLA open and maintain the indication for Duchenne-associated cardiomyopathy.To advance that path, Capricor proposed designating left ventricular ejection fraction (LVEF), a cardiac function measure, as the primary efficacy endpoint. While the FDA did not allow the formal change, it agreed to exercise regulatory flexibility in reviewing the data, indicating that strong cardiac results could support approval.<h2 class="st-heading-2">Manufacturing Update</h2>Capricor said its San Diego GMP facility, which produces the commercial-scale version of deramiocel, has passed its pre-license inspection (PLI) and that all chemistry, manufacturing, and controls (CMC) concerns noted in the CRL have been resolved.The company plans a Type 2 resubmission, triggering a six-month FDA review window, and said a strong efficacy signal could accelerate approval as early as 2026.If approved before Sept. 30, 2026, Capricor would qualify for a Priority Review Voucher (PRV) under its Rare Pediatric Disease Designation, potentially adding non-dilutive value. The company ended the third quarter with $98.6 million in cash, providing runway into late 2026, and remains eligible for an $80 million milestone from NS Pharma upon approval.<h2 class="st-heading-2">Stocktwits Traders Call RMAT Capricor’s ‘Secret Weapon’</h2>On Stocktwits, retail sentiment for Capricor was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:969/139;" src="https://news.stocktwits-cdn.com/capr_stock_jpg_674aa0a57c.webp" alt="capr stock.jpg" width="969" height="139"><figcaption>CAPR sentiment and message volume as of November 10 | Source: Stocktwits</figcaption></figure>Some users pointed to Capricor’s Regenerative Medicine Advanced Therapy (RMAT) designation as a potential catalyst. One user said the RMAT pathway was the company’s “secret weapon,” noting that Duchenne’s fatal nature and unmet medical need could allow the FDA to grant accelerated approval based on surrogate endpoints such as cardiac function improvements rather than long-term survival data.<stembedurl>https://stocktwits.com/WBinthehouse/message/635689643</stembedurl>Another user said the “best takeaway” from Capricor’s earnings call was the expectation of a “surprise data drop” within one to three weeks, adding that they were optimistic about positive top-line results from the study.<stembedurl>https://stocktwits.com/Bentradez/message/635689357</stembedurl>A third user said the FDA’s stated willingness to show flexibility could let Capricor “turn on the RMAT cheat code,” meaning the company could leverage its designation to pursue accelerated approval if left ventricular ejection fraction (LVEF) data are strong even when skeletal endpoints fall slightly short. The user described this as a potential “fallback” that could bring deramiocel to market months faster.<stembedurl>https://stocktwits.com/WBinthehouse/message/635687964</stembedurl><a href="https://stocktwits.com/symbol/CAPR">Capricor’s stock</a> has declined 60% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Capricor Therapeutics Stock Jumps After-Hours As Retail Cheers Fresh FDA Attempt After Duchenne Therapy Rejection

Capricor plans to resubmit its Duchenne therapy application in 2026 with new cardiac efficacy data.

Preview: Capricor Therapeutics's Earnings

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

$NVDA

$AAPL

$GOOG/$GOOGL

$MSFT

Which company ends 2025 with the largest market cap?

Current Price	$4.60
Prev Close	$4.64
Open	$4.45
Dividend Yield	0.00%
50-Day Moving Average	$6.39
Beta	1.19
Avg. Volume	1.17M
PE Ratio	-2.56

52-Week High	$20.75
52-Week Low	$4.30
Market Capitalization	$212.13M
EPS (Annual)	-$1.15
Price to Book	2.51
Revenue Per Employee	$139,190.41
Enterprise Value/EBITDA	N/A

CAPR
Capricor Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CAPR News

CAPRCapricor Therapeutics Inc